Published online 22 January 2004
Nucleic Acids Research, 2004, Vol. 32, No. 2 456-464
© 2004 Oxford University Press
Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2
Cancer Research UK DNA Repair Enzyme Group, Section of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, 237 Fulham Road, London SW3 6JB, UK and 1 Unité 9003 du CNRS, Ecole Supérieure de Biotechnologie de Strasbourg, Boulevard Sébastien Brant, B.P. 10413, F-67412 Illkirch Cedex, France
*To whom correspondence should be addressed. Tel: +44 20 7970 6045; Fax: +44 20 7970 6051; Email: Laurence.Pearl{at}icr.ac.uk
Poly(ADP-ribose) polymerase-1 (PARP-1) has become an important pharmacological target in the treatment of cancer due to its cellular role as a DNA-strand break sensor, which leads in part to resistance to some existing chemo- and radiological treatments. Inhibitors have now been developed which prevent PARP-1 from synthesizing poly(ADP-ribose) in response to DNA-breaks and potentiate the cytotoxicity of DNA damaging agents. However, with the recent discoveries of PARP-2, which has a similar DNA-damage dependent catalytic activity, and additional members containing the PARP catalytic signature, the isoform selectivity and resultant pharmacological effects of existing inhibitors are brought into question. We present here the crystal structure of the catalytic fragment of murine PARP-2, at 2.8 Å resolution, and compare this to the catalytic fragment of PARP-1, with an emphasis on providing a possible framework for rational drug design in order to develop future isoform-specific inhibitors.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Teotia and R. S. Lamb The Paralogous Genes RADICAL-INDUCED CELL DEATH1 and SIMILAR TO RCD ONE1 Have Partially Redundant Functions during Arabidopsis Development Plant Physiology, September 1, 2009; 151(1): 180 - 198. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Altmeyer, S. Messner, P. O. Hassa, M. Fey, and M. O. Hottiger Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites Nucleic Acids Res., June 1, 2009; 37(11): 3723 - 3738. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Robert, F. Dantzer, and B. Reina-San-Martin Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination J. Exp. Med., April 13, 2009; (2009) jem.20082468v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Eltze, R. Boer, T. Wagner, S. Weinbrenner, M. C. McDonald, C. Thiemermann, A. Burkle, and T. Klein Imidazoquinolinone, Imidazopyridine, and Isoquinolindione Derivatives as Novel and Potent Inhibitors of the Poly(ADP-ribose) Polymerase (PARP): A Comparison with Standard PARP Inhibitors Mol. Pharmacol., December 1, 2008; 74(6): 1587 - 1598. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bai, S. M. Houten, A. Huber, V. Schreiber, M. Watanabe, B. Kiss, G. de Murcia, J. Auwerx, and J. M.-d. Murcia Peroxisome Proliferator-activated Receptor (PPAR)-2 Controls Adipocyte Differentiation and Adipose Tissue Function through the Regulation of the Activity of the Retinoid X Receptor/PPAR{gamma} Heterodimer J. Biol. Chem., December 28, 2007; 282(52): 37738 - 37746. [Abstract] [Full Text] [PDF] |
||||




